Cellectis Preclinical Gene-Editing Candidate Lowers Lipids
The .HEAL-101 candidate uses TALE base editing to silence the APOC3 gene, with human clinical data expected in 2027.
Updated on Oct. 27, 2026 in Biotech
Live Poll
Do you believe genetic therapies are a better long-term option than traditional daily medications?
Cellectis has disclosed preclinical results for .HEAL-101, an experimental gene-editing candidate designed to target the APOC3 gene. The study, presented at the ESGCT congress, demonstrates that the treatment achieves significant protein knockdown in animal and cellular models.
Why it matters
APOC3 is a validated driver of elevated triglycerides, making it a high-value target for managing metabolic conditions. This research evaluates a permanent, liver-directed genetic approach to suppress the gene rather than relying on chronic daily medication.
The .HEAL-101 candidate demonstrated a 90% mean APOC3 editing rate in human hepatic cells and a 70% editing rate in mouse models. Researchers achieved a 67% reduction in APOC3 levels in disease-modeled mice, with editing restricted specifically to the liver.
The players
Cellectis
A gene-editing company that develops TALE-based tools and cell therapies for oncology and metabolic diseases.
The details
The treatment uses TALE base editors—proteins engineered to bind to specific DNA sequences and chemically convert one nucleotide base to another—delivered as mRNA within lipid nanoparticles. These microscopic fat-based spheres act as a delivery vehicle to shuttle the genetic editing machinery directly to the liver. Once inside, the TALE base editor permanently alters the APOC3 gene to silence its expression.
Timeline
September 14, 2026: The initial preclinical dataset was first disclosed.
October 27-30, 2026: The ESGCT Annual Congress was held in Hamburg, Germany.
October 29, 2026: Researchers presented findings during a poster session.
Second half of 2027: Preliminary clinical data from a trial in China is expected.
The Tech Race
Cellectis is competing in the dense field of liver-directed gene editing, which currently focuses on finding more precise ways to silence metabolic risk genes. These results update the company's progress on a permanent genetic alternative to existing daily lipid-lowering therapies.
This development is currently in preclinical research and is not available for patients or clinical use. Future availability depends on successful safety outcomes in upcoming Phase 1 trials.
The takeaway
Cellectis is moving toward a permanent genetic knockdown approach for metabolic targets, marking a shift away from traditional chronic treatments. Observers should track the upcoming investigator-initiated trial in China for the first safety data in human participants.
What happens next
Cellectis plans to initiate a Phase 1 investigator-initiated trial in China, with preliminary results expected in the second half of 2027.
Further reading
For broader trends in genetic medicine, visit our Biotech section.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you believe genetic therapies are a better long-term option than traditional daily medications?
